Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing pharmaceutical products for serious medical conditions. As of the reporting date, the company had one marketed product, ARCALYST® (rilonacept), approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS). The company maintains a robust pipeline of six clinical development programs, including late-stage candidates for oncology (aflibercept), ophthalmology (VEGF Trap-Eye), and inflammatory diseases (ARCALYST for gout), primarily developed in collaboration with sanofi-aventis and Bayer HealthCare.
Key Financial Metrics
| Metric (in millions) | 2008 | 2007 |
|---|---|---|
| Total Revenues | $238.5 | $125.0 |
| Net Loss | $(82.7) | $(105.6) |
| Net Loss Per Share (Basic & Diluted) | $(1.05) | $(1.59) |
| Research & Development Expenses | $278.0 | $201.6 |
| Cash, Cash Equivalents, and Marketable Securities | $527.5 | $846.3 |
| Net Cash Used in Operating Activities | $(89.1) | $27.4 (Provided) |
| Debt | $0 (Repaid in Oct 2008) | $200.0 (Convertible Notes) |
Revenue Composition (2008):
- Contract Research & Development: $192.2 million (Primarily from sanofi-aventis and Bayer HealthCare).
- Technology Licensing: $40.0 million (From AstraZeneca and Astellas).
- Net Product Sales (ARCALYST): $6.3 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 91% to $238.5 million, driven primarily by the initiation of the global antibody collaboration with sanofi-aventis in late 2007, which generated $154.0 million in contract research revenue in 2008.
- Expense Increase: Operating expenses rose to $328.3 million from $239.5 million. R&D expenses increased 38% to $278.0 million due to expanded clinical programs (VEGF Trap-Eye, ARCALYST, and monoclonal antibodies) and increased headcount (average 810 employees in 2008 vs. 627 in 2007).
- Debt Elimination: The company repurchased $82.5 million of its convertible senior subordinated notes in 2008 and repaid the remaining $117.5 million upon maturity in October 2008, resulting in zero long-term debt at year-end.
- Investment Portfolio: Cash and marketable securities decreased by approximately $319 million, reflecting the repayment of debt and increased operating cash usage, despite a net cash inflow from investing activities due to the sale of marketable securities.
Guidance, Outlook, and Risks
Management Outlook:
- ARCALYST: Management expects to ship $20–24 million of ARCALYST to U.S. distributors in 2009.
- Headcount: Average headcount is expected to increase to approximately 950–1,000 in 2009 to support expanded R&D and marketing activities.
- Liquidity: Management believes existing capital resources, including collaboration funding, will meet operating needs through at least 2012.
- Capital Expenditures: Expected to be $50–60 million in 2009, primarily for manufacturing expansion and new Tarrytown facilities.
Key Risks and Contingencies:
- Profitability: The company has a cumulative loss of $875.9 million since inception and expects to incur substantial losses for the foreseeable future.
- Collaboration Dependence: Significant reliance on sanofi-aventis and Bayer HealthCare for funding, development, and commercialization. Termination of these agreements could materially harm operations.
- Investment Risk: The company holds $278.0 million in marketable securities. Deterioration in credit quality (specifically asset-backed and corporate bonds) led to $2.5 million in impairment charges in 2008, with risk of further losses.
- Regulatory & Clinical: Success depends on obtaining regulatory approval for pipeline candidates (aflibercept, VEGF Trap-Eye) and achieving commercial success in rare disease markets (CAPS).
Investor Verification Checklist
- Collaboration Terms: Verify the specific reimbursement and profit-sharing formulas with sanofi-aventis and Bayer HealthCare, as these drive a significant portion of revenue and expense recognition.
- Investment Portfolio Quality: Review the composition of the $278 million marketable securities portfolio, specifically the exposure to asset-backed securities and corporate bonds, given the 2008 impairment charges.
- ARCALYST Commercialization: Monitor actual sales volumes and reimbursement rates for ARCALYST against the $20–24 million shipment guidance for 2009.
- Cash Burn Rate: Assess the sustainability of the current cash burn rate ($89 million used in operations in 2008) against the projected runway through 2012.
- Clinical Trial Milestones: Track enrollment and data readout dates for Phase 3 trials of aflibercept (oncology) and VEGF Trap-Eye (wet AMD), as these are critical value drivers.